Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
Phase 1 results of a phase 1/2 trial of CYT-0851, a first-in-class inhibitor of RAD51-mediated homologous recombination, in patients with advanced solid and hematologic cancers. Lynch, R. C., Munster, P. N., Advani, R. H., Hamadani, M., Spigel, D. R., Falchook, G., Patel, M. R., Siegel, D., Beri, N., Nowakowski, G. S., Palmisiano, N., Burness, M., Moore, K. N., Shapiro, G., Juric, D., Bradley, W. D., O'Shea, T. J., Renschler, M., Englert, J. M., Yap, T. A. LIPPINCOTT WILLIAMS & WILKINS. 2022
View details for Web of Science ID 000863680300977